Generic HIV Drugs — Enlightened Policy for Global Health
- 24 February 2005
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 352 (8) , 747-750
- https://doi.org/10.1056/nejmp048356
Abstract
The 2000 International AIDS Conference in Durban, South Africa, focused the world's attention on disparities between rich and poor countries with respect to access to antiretroviral drugs. At that time, an estimated 7000 people in Africa had access to effective combination antiretroviral regimens. Though the number exceeds 100,000 today, it is still a far cry from the 8 million who are thought to require such therapy. In response, in 2003, the World Health Organization (WHO) launched an ambitious program termed “3 by 5” in an attempt to treat at least 3 million infected people by the end of 2005.Keywords
This publication has 3 references indexed in Scilit:
- Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistanceThe Lancet, 2002
- Viral Load and Heterosexual Transmission of Human Immunodeficiency Virus Type 1New England Journal of Medicine, 2000
- Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patientsAIDS, 1996